PuSH - Publikationsserver des Helmholtz Zentrums München

Costanzo, V.* ; Ratre, Y.K.* ; Andretta, E.* ; Acharya, R.* ; Bhaskar, L.V.K.S.* ; Verma, H.K.

A comprehensive review of cancer drug-induced cardiotoxicity in blood cancer patients: Current perspectives and therapeutic strategies.

Curr. Treat. Options Oncol. 25, 465-495 (2024)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Cardiotoxicity has emerged as a serious outcome catalyzed by various therapeutic targets in the field of cancer treatment, which includes chemotherapy, radiation, and targeted therapies. The growing significance of cancer drug-induced cardiotoxicity (CDIC) and radiation-induced cardiotoxicity (CRIC) necessitates immediate attention. This article intricately unveils how cancer treatments cause cardiotoxicity, which is exacerbated by patient-specific risks. In particular, drugs like anthracyclines, alkylating agents, and tyrosine kinase inhibitors pose a risk, along with factors such as hypertension and diabetes. Mechanistic insights into oxidative stress and topoisomerase-II-B inhibition are crucial, while cardiac biomarkers show early damage. Timely intervention and prompt treatment, especially with specific agents like dexrazoxane and beta-blockers, are pivotal in the proactive management of CDIC.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Korrespondenzautor
Schlagwörter Blood Cancer ; Cardiotoxicity ; Cardiovascular Disease ; Immunotherapy ; Therapeutics; Chronic Myeloid-leukemia; Anthracycline-associated Cardiotoxicity; Chronic Lymphocytic-leukemia; Renal-cell Carcinoma; Long-term Survivors; Cardiovascular Toxicity; Hodgkin Lymphoma; Heart-disease; Doxorubicin Cardiotoxicity; Cardiac-disease
ISSN (print) / ISBN 1527-2729
e-ISSN 1534-6277
Zeitschrift Current Treatment Options in Oncology
Quellenangaben Band: 25, Heft: 4, Seiten: 465-495 Artikelnummer: , Supplement: ,
Verlag Springer
Verlagsort One New York Plaza, Suite 4600, New York, Ny, United States
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Lung Health and Immunity (LHI)